In addition, CD45+CD3+ human T cells decreased gradually after tumor eradication without body weight loss after infusion (Fig. 1d), suggesting that the anti-CD19 CART-aIL6/Fc CART cells were effective and safe in the mouse model. This evidence concerns the gene PTPRC and neoplasm.